Navigation Links
Thesan Pharmaceuticals Appoints Dr. Bhaskar Chaudhuri to the Board of Directors August 2014
Date:8/25/2014

SAN DIEGO, Aug. 25, 2014 /PRNewswire/ -- Thesan Pharmaceuticals announced today the appointment of Bhaskar Chaudhuri Ph.D., to its Board of Directors. Dr. Chaudhuri has more than 25 years of experience in pharmaceuticals management, drug research & development, and commercialization in the US, EU and emerging markets. He has led the development and FDA approval of multiple NDAs and ANDAs. Most recently, Dr. Chaudhuri served as President of Valeant Pharmaceuticals before becoming an Operating Partner at Frazier Healthcare. Prior to joining Valeant, Dr. Chaudhuri served as President and CEO of Dow Pharmaceuticals leading up to their acquisition by Valeant. Before Dow, Dr. Chaudhuri worked at Bertek Pharmaceuticals (a subsidiary of Mylan Laboratories) as Executive Vice President of Scientific Affairs and as the General Manager of the Dermatology Division of Mylan Laboratories. Dr. Chaudhuri holds a Doctorate in Physical Pharmacy. He also serves on the Board of multiple pharmaceutical companies.

"We are delighted to have Bhaskar join our Board at this time," said Gordon Foulkes, Thesan's CEO. "His superb track record of developing dermatology drugs, his commercialization expertise, and leadership role in the sale of multiple dermatology companies will be a tremendous help to Thesan going forward as we continue to build our Executive leadership team for the future."

"I am truly honored to be included as part of the Thesan team," Dr. Chaudhuri added. "The current portfolio of breakthrough products managed by a world class team gives Thesan the foundation to be a preeminent Dermatology company. I look forward to contributing towards the growth of Thesan and be part of a leading Dermatology organization."

Also at this time, in connection with the recent Series B financing, Dr. Peter Moldt of Novo Ventures will become the new Novo Board member to represent their investment in Thesan. Dr. Moldt has had extensive experience in the biotechnology industry, serving either as CEO, COO or head of R&D in a number of successful companies, including Curalogic A/S, which he founded and then took public in 2006. Dr. Moldt joined Novo Ventures in 2009.

About Thesan Pharmaceuticals, Inc.

Thesan is a biotechnology company focused on the development and commercialization of novel drugs for the treatment of dermatological conditions.
For more information visit: www.thesanpharma.com

Contact:
J. Gordon Foulkes, Ph.D.
Chief Executive Officer
Thesan Pharmaceuticals, Inc.
Info@ThesanPharma.com


'/>"/>
SOURCE Thesan Pharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. Thesan Pharmaceuticals udpeger Dr. Bhaskar Chaudhuri til bestyrelsen i august 2014
2. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
3. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
4. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
5. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
6. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
7. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
8. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
9. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
10. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
11. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... Advanced Polymer ... hire of Dr. Sigmund “Sig” Floyd as Vice President ? Global Business Development. ... development activities. , “Dr. Floyd’s career has spanned 30 years in the chemicals ...
(Date:3/22/2017)... March 22, 2017  UBM and the Massachusetts ... their extended partnership and the third annual Massachusetts Medtech ... the 21 st Annual MassMEDIC Conference held ... May 3-4, 2017. MassMEDIC will ... (ADVAMED) President and CEO, Scott Whitaker , ...
(Date:3/22/2017)... March 22, 2017 The global ... a research report by Transparency Market Research (TMR). The ... Inc., and AbbVie Inc., accounted for a share of ... players in this market are focusing aggressively on mergers, ... which is likely to lead to market consolidation in ...
(Date:3/22/2017)... , March 22, 2017   ... independent provider of product and service solutions ... that it has acquired EPL Archives, Inc., ... customers across the entire regulated product research, ... sample, document storage and ancillary services. EPL ...
Breaking Biology Technology:
(Date:2/21/2017)... 21, 2017 Der weltweite Biobanking-Sektor ... Nach einem Gespräch mit mehr als 50 Vertretern aus verschiedenen ... überwinden gilt, um diese Prognose zu realisieren. ... Zu ... der finanziellen Mittel für die Biobank, die Implementierung Zeit ...
(Date:2/14/2017)... , Feb. 14, 2017  Wake Forest Baptist Medical ... its new chief executive officer (CEO). Freischlag joins the ... John D. McConnell , M.D., who last year announced ... the Medical Center, after leading it since 2008.   ... scope of Wake Forest Baptist,s academic health system, which ...
(Date:2/13/2017)... , Feb. 13, 2017 Former 9/11 ... Senate Judiciary Committee, Janice Kephart of Identity ... President Donald Trump,s "Executive Order: Protecting the ... (Jan. 27, 2017):  "As President Trump,s ,Travel ... Circuit has now essentially banned the travel ban, it ...
Breaking Biology News(10 mins):